The longevity society.
Journal
The lancet. Healthy longevity
ISSN: 2666-7568
Titre abrégé: Lancet Healthy Longev
Pays: England
ID NLM: 101773309
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
23
02
2021
revised:
22
09
2021
accepted:
23
09
2021
entrez:
13
9
2022
pubmed:
14
9
2022
medline:
15
9
2022
Statut:
ppublish
Résumé
As the demographic transition enters a new stage of a longevity transition, focus needs to extend beyond an ageing society towards a longevity society. An ageing society focuses on changes in the age structure of the population, whereas a longevity society seeks to exploit the advantages of longer lives through changes in how we age. Achieving a longevity society requires substantial changes in the life course and social norms, and involves an epidemiological transition towards a focus on delaying the negative effects of ageing. The broad changes required to achieve healthy longevity include an increased focus on healthy life expectancy, a shift from intervention towards preventive health, a major public health agenda to avoid increases in health inequality, the establishment of longevity councils to ensure coordinated policy across government departments, and intergenerational assessment of policies, to ensure that in adapting to longer lives, policies are not skewed towards older people. A longevity society represents a new stage for humanity and requires deep-seated notions about age and ageing to be challenged if society is to make the best use of the additional time that longevity brings.
Identifiants
pubmed: 36098038
pii: S2666-7568(21)00247-6
doi: 10.1016/S2666-7568(21)00247-6
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e820-e827Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests AJS is a cofounder of the not-for-profit The Longevity Forum, an adviser to Genflow Biosciences, and serves in non-paid roles on a number of advisory boards. In 2021, he received a speaker honoraria from Elsevier for speaking at an event on age diversity.